Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Akoya Biosciences Inc (AKYA)

Akoya Biosciences Inc (AKYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stock Index Futures Tread Water Ahead of Key U.S. PPI Data and Powell Remarks

June S&P 500 E-Mini futures (ESM24) are up +0.02%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.03% this morning as investors geared up for crucial U.S. producer inflation data while also awaiting...

ESM24 : 5,318.50 (-0.03%)
NQM24 : 18,634.50 (-0.08%)
INCY : 57.16 (+0.53%)
INTC : 31.80 (-0.72%)
SQSP : 43.38 (+0.30%)
AMAT : 213.06 (-0.45%)
HD : 341.17 (-0.46%)
ALC.Z.IX : 79.980 (-1.06%)
DHER.D.DX : 31.700 (-2.22%)
RHM.D.DX : 512.600 (-0.10%)
FULC : 7.52 (-3.59%)
FOLD : 9.46 (-0.42%)
Why Shares of Akoya Biosciences Jumped on Tuesday

A rash of insider buying buoyed investor confidence in the medical instrument company.

AKYA : 2.87 (-1.03%)
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -6.52% and 5.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 2.87 (-1.03%)
CELU : 3.05 (unch)
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 2.87 (-1.03%)
ACET : 1.6550 (+5.41%)
Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Rapt Therapeutics (RAPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RAPT : 4.07 (-1.69%)
AKYA : 2.87 (-1.03%)
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 1.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 3.00 (+3.81%)
AKYA : 2.87 (-1.03%)
Certara, Inc. (CERT) Tops Q4 Earnings and Revenue Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of 14.29% and 4.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CERT : 16.52 (+0.30%)
AKYA : 2.87 (-1.03%)
Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 1.10% and 6.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

RXDX : 199.92 (+0.09%)
AKYA : 2.87 (-1.03%)
Will Akoya Biosciences (AKYA) Report Negative Earnings Next Week? What You Should Know

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKYA : 2.87 (-1.03%)
ICPT : 19.00 (+0.21%)
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates

Ligand (LGND) delivered earnings and revenue surprises of 10.57% and 24.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LGND : 86.68 (+1.95%)
AKYA : 2.87 (-1.03%)

Barchart Exclusives

Up 88% in 2023, Can Wayfair Stock Repeat The Feat in 2024?
Most Wall Street analysts have a very optimistic outlook for this consumer stock, expecting it to soar more than 60% from current levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar